Říhová B - Search Results

1

[History of Immuno-therapy - from Coley Toxins to Check-points of the Immune Reaction].

Říhová B, Šťastný M. Říhová B, et al. Klin Onkol. 2015;28 Suppl 4:4S8-14. Klin Onkol. 2015. PMID: 26647883 Czech.

2

[Escape Strategies of Tumors from Immune Surveillence].

Šťastný M, Říhová B. Šťastný M, et al. Among authors: rihova b. Klin Onkol. 2015;28 Suppl 4:4S28-37. doi: 10.14735/amko20154s28. Klin Onkol. 2015. PMID: 26647886 Review. Czech.

3

Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs.

Ríhová B, Strohalm J, Kubácková K, Jelínková M, Hovorka O, Kovár M, Plocová D, Sírová M, St'astný M, Rozprimová L, Ulbrich K. Ríhová B, et al. J Control Release. 2002 Jan 17;78(1-3):97-114. doi: 10.1016/s0168-3659(01)00489-8. J Control Release. 2002. PMID: 11772452

4

[Use of targeted drugs in antineoplastic and immunosuppressive therapy].

Ríhová B, Trohalm J, Jelínková M, Stastný M, Hovorka O, Plocová D, Subr V, Ulbrich K. Ríhová B, et al. Bratisl Lek Listy. 1998 Aug-Sep;99(8-9):439-46. Bratisl Lek Listy. 1998. PMID: 9810768 Review. Czech. No abstract available.

5

Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.

Ríhová B, Jelínková M, Strohalm J, St'astný M, Hovorka O, Plocová D, Kovár M, Dráberová L, Ulbrich K. Ríhová B, et al. Bioconjug Chem. 2000 Sep-Oct;11(5):664-73. doi: 10.1021/bc9901696. Bioconjug Chem. 2000. PMID: 10995209

6

HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.

Kovár M, Mrkvan T, Strohalm J, Etrych T, Ulbrich K, Stastný M, Ríhová B. Kovár M, et al. Among authors: rihova b. J Control Release. 2003 Oct 30;92(3):315-30. doi: 10.1016/s0168-3659(03)00340-7. J Control Release. 2003. PMID: 14568412

7

Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens.

Jelínková M, Strohalm J, Plocová D, Subr V, St'astný M, Ulbrich K, Ríhová B. Jelínková M, et al. Among authors: rihova b. J Control Release. 1998 Mar 31;52(3):253-70. doi: 10.1016/s0168-3659(97)00210-1. J Control Release. 1998. PMID: 9743446

8

Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.

Ríhová B, Etrych T, Pechar M, Jelínková M, Stastný M, Hovorka O, Kovár M, Ulbrich K. Ríhová B, et al. J Control Release. 2001 Jul 6;74(1-3):225-32. doi: 10.1016/s0168-3659(01)00320-0. J Control Release. 2001. PMID: 11489498

9

Differences in the intracellular fate of free and polymer-bound doxorubicin.

Hovorka O, St'astný M, Etrych T, Subr V, Strohalm J, Ulbrich K, Ríhová B. Hovorka O, et al. Among authors: rihova b. J Control Release. 2002 Apr 23;80(1-3):101-17. doi: 10.1016/s0168-3659(02)00016-0. J Control Release. 2002. PMID: 11943391

10

HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia.

St'astný M, Plocová D, Etrych T, Ulbrich K, Ríhová B. St'astný M, et al. Among authors: rihova b. Eur J Cancer. 2002 Mar;38(4):602-8. doi: 10.1016/s0959-8049(01)00421-x. Eur J Cancer. 2002. PMID: 11872356

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page